SEC Filing Summary: AspenBio Pharma, Inc. (Form 10-K)
Business Context and Reporting Period
Company: AspenBio Pharma, Inc.
Reporting Period: Fiscal year ended December 31, 2010.
Business Overview: AspenBio is a biotechnology company developing products for human diagnostics and animal health. Its lead product, AppyScore, is a blood-based diagnostic test for acute appendicitis intended to reduce unnecessary CT scans. The company also develops recombinant hormone analogs for livestock reproduction (BoviPure LH and FSH), which are licensed to Novartis Animal Health. In 2010, the company substantially suspended its historical antigen manufacturing business to focus resources on AppyScore and animal health product development.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenues | $370,000 | $291,000 |
| Gross Profit | $12,000 | $(419,000) |
| Net Loss | $(13,338,000) | $(15,518,000) |
| Loss Per Share (Basic/Diluted) | $(0.34) | $(0.47) |
| Research & Development Expenses | $6,019,000 | $8,714,000 |
| Cash and Cash Equivalents (Year End) | $8,908,000 | $13,367,000 |
| Working Capital | $9,575,000 | $11,153,000 |
| Total Debt (Long-term + Current) | $2,821,000 | $2,763,000 |
Note: Revenues are derived primarily from the sale of purified protein antigens and amortization of license fees from Novartis. The company has no commercial revenue from its pipeline products.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27% to $370,000, driven by the timing of customer orders for antigen products before production was suspended.
- Reduced R&D Spend: Research and development expenses decreased 31% to $6.0 million, primarily due to the completion of major AppyScore clinical trials in 2009 and reduced consulting costs.
- Improved Gross Margin: The company moved from a gross loss of 144% in 2009 to a gross profit of 3% in 2010. This was due to a reduction in inventory write-downs ($153,000 in 2010 vs. $400,000 in 2009) and the cessation of antigen production overhead allocation.
- Capital Raise: In May 2010, the company completed a registered direct offering, raising approximately $9.1 million in net proceeds to fund operations through late 2011.
Guidance, Outlook, and Risks
Product Development Status:
- AppyScore: The company withdrew its 510(k) submission for the ELISA-based test in 2010 due to low specificity in clinical trials caused by sample transport issues. The company is now developing a cassette-based version to mitigate these issues. A Phase I clinical study is underway, with a pivotal trial planned for 2011.
- Novartis Partnership: A pilot study for BoviPure LH and FSH was completed in late 2010. Preliminary results indicated failure to meet success criteria. Novartis has requested a refund of $900,000 in milestone payments, though the request is deferred pending review of the final report.
Outlook: Management anticipates continued operating losses in 2011. R&D expenditures are expected to increase slightly compared to 2010 due to pre-clinical and clinical trial work for the new AppyScore cassette system. Antigen sales are expected to decline significantly in 2011.
Key Risks and Contingencies:
- Regulatory Risk: No assurance exists that AppyScore will obtain FDA clearance. Failure to do so would prevent commercialization and render prior R&D investments impaired.
- Liquidity: While current cash reserves are sufficient for near-term needs, the company may require additional capital in 2011 if development costs exceed projections or if the Novartis agreement is terminated.
- Legal Proceedings: The company is defending against two securities class action lawsuits (filed in 2010) alleging fraud and misrepresentation regarding AppyScore. The company believes the allegations are without merit.
- Stock Listing: The company's stock price fell below the NASDAQ minimum bid price of $1.00. The company received an extension to regain compliance by August 2011, potentially via a reverse stock split.
Investor Verification Checklist
- Novartis Milestone Refund: Verify the final outcome of the Novartis pilot study review and whether the $900,000 refund request will be honored or if the partnership will be terminated.
- AppyScore Clinical Data: Review the results of the ongoing Phase I study for the cassette-based AppyScore test to confirm if sample handling issues have been resolved.
- Cash Burn Rate: Monitor quarterly cash flow statements to ensure the $9.1 million raised in May 2010 is sufficient to fund operations through the planned 2011 pivotal trial.
- NASDAQ Compliance: Track the stock price to determine if a reverse stock split is required to maintain NASDAQ listing status.
- Legal Status: Monitor the status of the pending securities class action lawsuits for any settlements or adverse rulings.